28 January 2026 : Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkish Oncology Centers
Halil Göksel Güzel
ABCDEF 1*, Arif Hakan Önder ABDEF 1, Yusuf İlhan BD 2, Onur Yazdan Balçık BD 3, Banu Öztürk ABEF 1
DOI: 10.12659/MSM.951027
Med Sci Monit 2026; 32:e951027
Table 3 Comparison of hospitals in metropolitan areas and hospitals in other cities.
| Metropolitan hospitals (n=33) | Hospitals in other cities (n=53) | P value | |
|---|---|---|---|
| 2 (0–50) | 0 (0–25) | 0.002 | |
| 0.520 | |||
| 2 (0–42) | 0 (0–25) | ||
| 2 (0–5) | 0 (0–6) | ||
| Yes, easily | 25 (75.8) | 20 (37.7) | |
| Sometimes, hardly | 3 (9.1) | 25 (47.2) | |
| No, never | 2 (6.1) | 3 (5.7) | |
| Not answered | 3 (9.1) | 5 (9.4) | |
| Breast cancer | 9 (27.3) | 11 (20.8) | |
| Lung cancer | 16 (48.5) | 23 (43.4) | |
| Gastrointestinal cancers | 1 (3.0) | 4 (7.5) | |
| Prostate-urinary bladder cancer | 4 (12.1) | 3 (5.7) | |
| Renal cell carcinoma | 0 (0.0) | 0 (0.0) | |
| Melanoma | 0 (0.0) | 2 (3.8) | |
| Other | 1 (1.2) | 0 (0.0) | |
| Unable to reach any clinical trials | 2 (6.1) | 9 (17.0) | |
| Not answered | 0 (0.0) | 1 (1.9) | |
| NGS available | 25 (75.8) | 11 (20.8) | |
| NGS unavailable but reachable | 8 (24.2) | 32 (60.4) | |
| NGS unavailable and unreachable | 0 (0.0) | 10 (18.9) | |
| NGS – next-generation sequencing. | |||